Interpace Biosciences, Inc. Announces Board Changes
January 17, 2020 at 07:02 pm IST
Share
Interpace Biosciences, Inc. announced that On January 14, 2020, the Board adopted resolutions to appoint the Investors’ designees to the Board upon the Closing. On January 15, 2020, effective immediately upon the Closing, Ampersand re-designated Eric Lev (a Partner at Ampersand Capital Partners) and Robert Gorman to the Board as a Class I and Class II director, respectively, and 1315 Capital designated Edward Chan (an employee of 1315 Capital Management, LLC) to the Board as a Class II director, who were each thereby appointed and elected to the Board. As a Class I director, Mr. Lev will serve until the Company’s 2022 annual meeting of stockholders and, as Class II directors, Messrs. Gorman and Chan will serve until the Company’s 2021 annual meeting of stockholders, or, in each case, until their respective successors are elected and qualified, or until their earlier death, resignation or removal. Messrs. Chan, Gorman and Lev serve on the Board as non-employee directors.
Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Its clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer by leveraging the technology in personalized medicine for improved patient diagnosis and management. It has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, RespriDX, and BarreGEN. PancraGEN is for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts. PanDNA is a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors. ThyGeNEXT is for the diagnosis of thyroid cancer from thyroid nodules. RespriDX differentiates lung cancer of primary versus metastatic origin.